Morepen Laboratories (500288) Stock Overview
Develops, manufactures, markets, and sells active pharmaceutical ingredients (APIs), branded and generic formulations, and home health products in India, the United States, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 1/6 |
| Financial Health | 6/6 |
| Dividends | 2/6 |
500288 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Morepen Laboratories Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹39.81 |
| 52 Week High | ₹70.40 |
| 52 Week Low | ₹33.47 |
| Beta | 0.62 |
| 1 Month Change | 1.56% |
| 3 Month Change | -6.15% |
| 1 Year Change | -19.82% |
| 3 Year Change | 51.83% |
| 5 Year Change | 11.67% |
| Change since IPO | -64.14% |
Recent News & Updates
Recent updates
Shareholder Returns
| 500288 | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | -9.1% | -0.1% | -3.0% |
| 1Y | -19.8% | 6.8% | 7.8% |
Return vs Industry: 500288 underperformed the Indian Pharmaceuticals industry which returned 6.9% over the past year.
Return vs Market: 500288 underperformed the Indian Market which returned 8.8% over the past year.
Price Volatility
| 500288 volatility | |
|---|---|
| 500288 Average Weekly Movement | 7.4% |
| Pharmaceuticals Industry Average Movement | 5.4% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in IN Market | 9.1% |
| 10% least volatile stocks in IN Market | 3.8% |
Stable Share Price: 500288 has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: 500288's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1984 | 1,814 | Sushil Suri | www.morepen.com |
Morepen Laboratories Limited develops, manufactures, markets, and sells active pharmaceutical ingredients (APIs), branded and generic formulations, and home health products in India, the United States, and internationally. The company offers APIs for anti-histaminic, anti-asthmatic, anti-lipemic, anti-hypertensive, anti-diabetic, anti-coagulant, anti-ulcerative, and anti-depressant drugs; and home diagnostic products, such as air purifiers, sphygmomanometers, blood glucose test strips, blood pressure monitors, breathe free vaporizers, stethoscopes, digital thermometers, blood glucose monitors, nebulizers, heat belts, and pulse oximeters. It also provides OTC and healthcare products, including fever X for fever; Pain X for pain; Fiber-X for constipation; sat isabgol; Acidity X for acidity; Burnol, a first degree/minor burns cream; and formulations for nutrition and probiotics, gastroenterology, antibiotics, gynecology, anti-allergic, and central nervous system, as well as cardiology, diabetology, and nutraceuticals.
Morepen Laboratories Limited Fundamentals Summary
| 500288 fundamental statistics | |
|---|---|
| Market cap | ₹21.81b |
| Earnings (TTM) | ₹994.48m |
| Revenue (TTM) | ₹17.87b |
Is 500288 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 500288 income statement (TTM) | |
|---|---|
| Revenue | ₹17.87b |
| Cost of Revenue | ₹11.70b |
| Gross Profit | ₹6.17b |
| Other Expenses | ₹5.18b |
| Earnings | ₹994.48m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.81 |
| Gross Margin | 34.53% |
| Net Profit Margin | 5.57% |
| Debt/Equity Ratio | 13.2% |
How did 500288 perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/03/06 03:45 |
| End of Day Share Price | 2026/03/06 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Morepen Laboratories Limited is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Vijay Madunala | FirstCall Research |